Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

HIF PHD1 Inhibitors

Hypoxia-inducible factor prolyl hydroxylase domain-containing protein 1 (HIF PHD1) is a critical enzyme involved in the cellular response to oxygen levels. It functions as part of the oxygen-sensing mechanism that regulates the stability and activity of hypoxia-inducible factors (HIFs), transcription factors that mediate adaptive responses to low oxygen conditions (hypoxia). HIF PHD1 hydroxylates specific proline residues on HIF-α subunits under normoxic conditions, a post-translational modification that signals for the proteasomal degradation of HIF-α via the von Hippel-Lindau (VHL) ubiquitination complex. This process effectively keeps HIF-α levels low during normal oxygen levels, thus preventing the activation of hypoxia-responsive genes. Under hypoxic conditions, the activity of HIF PHD1 is diminished due to the limited availability of oxygen, its substrate, leading to the stabilization of HIF-α, its translocation to the nucleus, dimerization with HIF-β, and subsequent activation of hypoxia-responsive gene expression. This regulatory mechanism allows cells to adapt to varying oxygen levels by altering gene expression profiles, influencing processes such as angiogenesis, metabolism, and erythropoiesis.The inhibition of HIF PHD1 represents a targeted approach to influence the cellular response to oxygen availability, effectively simulating a hypoxic state under normoxic conditions by stabilizing HIF-α and activating hypoxia-responsive pathways. Inhibition can be achieved through various means, including genetic manipulation or the use of small molecule inhibitors that directly interfere with the catalytic activity of HIF PHD1. These inhibitors typically function by occupying the active site of HIF PHD1, preventing the binding of its substrates (oxygen, 2-oxoglutarate) or the catalysis of the hydroxylation reaction. Some inhibitors mimic the structure of 2-oxoglutarate, the co-substrate of the hydroxylation reaction, thereby competing with it for binding to HIF PHD1. Others may interfere with the binding of iron, a critical cofactor for the enzymatic activity of HIF PHD1.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

N-Oxalylglycine

5262-39-5sc-202720
sc-202720A
10 mg
100 mg
$53.00
$153.00
5
(1)

N-Oxalylglycine (CAS 5262-39-5) is a chemical compound known for its role as an inhibitor of HIF PHD1 (Hypoxia-Inducible Factor Prolyl Hydroxylase 1). It exerts its action by inhibiting the hydroxylation of HIF (Hypoxia-Inducible Factor) proteins, which are critical regulators of cellular responses to low oxygen levels. By targeting PHD1, N-Oxalylglycine can potentially modulate the cellular response to hypoxia and impact various oxygen-sensitive processes.

N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine-d3

808118-40-3 unlabeledsc-488006
10 mg
$12000.00
(0)

N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine-d3 acts as an inhibitor of HIF-PHD1, effectively mimicking hypoxic conditions within cells. This action stabilizes hypoxia-inducible factors (HIFs), leading to increased transcription of erythropoietin (EPO) and promoting red blood cell production. The mechanism of inhibition disrupts the normal oxygen-sensing capabilities of the cell, facilitating the endogenous production of EPO.

BAY 85-3934

1154028-82-6sc-507384
5 mg
$205.00
(0)

Roxadustat (FG-4592) acts as an inhibitor of HIF-PHD1, effectively mimicking hypoxic conditions within cells. This action stabilizes hypoxia-inducible factors (HIFs), leading to increased transcription of erythropoietin (EPO) and promoting red blood cell production. The mechanism of inhibition disrupts the normal oxygen-sensing capabilities of the cell, facilitating the endogenous production of EPO.